KOL Views: How much of a threat is AstraZeneca’s triple combination in the competitive COPD space?

AstraZeneca reported that PT101 – a triple combination therapy involving budesonide, glycopyrronium and formoterol fumarate – significantly improved lung function on six of seven primary endpoints versus a pair of dual therapies in the Phase III KRONOS trial in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

To provide FirstWord readers with rapid feedback on PT101’s profile and how it could potentially compete with the likes GlaxoSmithKline and Innoviva’s triplet Trelegy Ellipta, we are hosting an expert call with a key opinion leader (KOL) later this week.

Key topics that will be discussed during the call include, among other things… how impressive is PT101’s top-line performance; which of the nine endpoints – seven focused on lung function – are most important, and which would be the most problematic to miss; feedback on Trelegy Ellipta’s profile and how it is being utilised; how much of a disadvantage is PT010’s twice-daily dosing schedule; and thoughts on what it would need to demonstrate to compete effectively with once-daily Trelegy?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the commercial prospects for AstraZeneca’s PT101.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.